Overall, we have shown that STs, and in particular ST3GAL4 and ST3GAL3 that lead to the sLex/a biosynthesis can be considered as potential therapeutic targets against pancreatic cancer. The gene discussed is ST3GAL3; the disease is familial pancreatic carcinoma.